Benitec Biopharma Inc.
NASDAQ:BNTCBiotechnology
+$0.36 today
- Market cap
- $288.53M
- Beta
- 0.28
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.99
Volume 0.13M
Average 0.11M
BNTC Other Current Assets
Current assets not reported separately, such as prepaid expenses.
Benitec Biopharma Inc.NASDAQ: BNTC
Other Current Assets · Q3 FY2026 · quarter ended Mar 2026
Other current assets rises 195.5% from a year ago
Other current assets stood at $1.25M at the end of Q3 FY2026, up 195.5% from a year earlier and up 85.6% from the prior quarter. Over 3 fiscal years it compounded at +275.5% a year.
Context
- Other current assets amounted to 0.7% of total assets at the end of Q3 FY2026, up 0.3 pp from a year earlier.
- Other current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current assets keeps rising in the next quarterly balance sheet after a +195.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 741K USD
- Year-over-year change
- +28.0%
- 4-year CAGR
- +165.1%
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 741K | +28.0% |
| FY2024 | 2024-06-30 | 579K | +4353.8% |
| FY2023 | 2023-06-30 | 13K | -7.1% |
| FY2022 | 2022-06-30 | 14K | -6.7% |
| FY2021 | 2021-06-30 | 15K | — |
Other Current Assets vs competitors
How BNTC compares with its peers on the latest reported figures
- BNTC's Mar 2026 other current assets of $1.25M is the 9th highest of the 10 companies compared; the peer median is $3.57M.
- Its year-over-year change of +195.5% is the 3rd highest of 10, against a peer median of +5.9%.
- Other current assets amounts to 0.7% of total assets for BNTC, versus a peer median of 1.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $11.42M | +595.3% | +75.2% | 2.1% | |
| Mar 2026 | $6.7M | +8.6% | -8.6% | 11.8% | |
| Mar 2026 | $5.23M | +39.6% | +10.2% | 2.5% | |
| Mar 2026 | $4.11M | -92.7% | +34.6% | 0.8% | |
| Mar 2026 | $3.57M | +257.6% | +19.4% | 1.4% | |
| Mar 2026 | $2.98M | -11.5% | +80.3% | 0.7% | |
| Mar 2026 | $1.98M | +5.9% | -0.3% | 1.8% | |
| Mar 2026 | $1.58M | -14.8% | -4.3% | 10.0% | |
| Mar 2026 | $1.25M | +195.5% | +275.5% | 0.7% | |
| Mar 2026 | $473K | -80.1% | +243.8% | 0.2% | |
| Peer median (excluding BNTC) | $3.57M | +5.9% | +19.4% | 1.8% | |
Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Benitec Biopharma Inc.
NASDAQ:BNTC
Intrinsic Alpha fair value
Locked
Current Price
$8.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.